#METABOLOMICS WORKBENCH SIMR_Core_Facility_20221018_005146 DATATRACK_ID:3516 STUDY_ID:ST002317 ANALYSIS_ID:AN003784 PROJECT_ID:PR001485 VERSION 1 CREATED_ON October 19, 2022, 8:57 am #PROJECT PR:PROJECT_TITLE Mass spectroscopy‑based proteomics and metabolomics analysis of PR:PROJECT_TITLE triple‑positive breast cancer cells treated with tamoxifen and/ or trastuzumab PR:PROJECT_TYPE LC-MS/MS PR:PROJECT_SUMMARY HER2-enriched breast cancer with high levels of hormone receptor expression, PR:PROJECT_SUMMARY known as "triple positive" breast cancer, may represent a new entity with a PR:PROJECT_SUMMARY relatively favourable prognosis against which the combination of chemotherapy, PR:PROJECT_SUMMARY HER-2 inhibition, and endocrine treatment may be considered overtreatment. We PR:PROJECT_SUMMARY explored the effect of the anticancer drugs tamoxifen and trastuzumab, both PR:PROJECT_SUMMARY separately and in combination, on the integrated proteomic and metabolic profile PR:PROJECT_SUMMARY of "triple positive" breast cancer cells (BT-474). Method We employed PR:PROJECT_SUMMARY ultra-high-performance liquid chromatography-quadrupole time of flight mass PR:PROJECT_SUMMARY spectrometry using a Bruker timsTOF to investigate changes in BT-474 cell line PR:PROJECT_SUMMARY treated with either tamoxifen, trastuzumab or a combination. Differentially PR:PROJECT_SUMMARY abundant metabolites were identified using the Bruker Human Metabolome Database PR:PROJECT_SUMMARY metabolite library and proteins using the Uniprot proteome for Homo sapiens PR:PROJECT_SUMMARY using MetaboScape and MaxQuant, respectively, for identification and PR:PROJECT_SUMMARY quantitation. Results A total of 77 proteins and 85 metabolites were found to PR:PROJECT_SUMMARY significantly differ in abundance in BT-474 treated cells with tamoxifen 5 PR:PROJECT_SUMMARY μM/and or trastuzumab 2.5 μM. Findings suggest that by targeting important PR:PROJECT_SUMMARY cellular signalling pathways which regulate cell growth, apoptosis, PR:PROJECT_SUMMARY proliferation, and chemoresistance, these medicines have a considerable PR:PROJECT_SUMMARY anti-growth effect in BT-474 cells. Pathways enriched for dysregulation include PR:PROJECT_SUMMARY RNA splicing, neutrophil degranulation and activation, cellular redox PR:PROJECT_SUMMARY homeostasis, mitochondrial transmembrane transport, ferroptosis and necroptosis, PR:PROJECT_SUMMARY ABC transporters and central carbon metabolism. Conclusion Our findings in PR:PROJECT_SUMMARY protein and metabolite level research revealed that anti-cancer drug therapy had PR:PROJECT_SUMMARY a significant impact on the key signalling pathways and molecular processes in PR:PROJECT_SUMMARY triple positive BT-474 cell lines. PR:INSTITUTE Sharjah Institute for Medical Research PR:DEPARTMENT Sharjah Institute for Medical Research PR:LABORATORY Biomarker Discovery Group PR:LAST_NAME Facility PR:FIRST_NAME Core PR:ADDRESS M32, SIMR, College of Pharmacy, Health Sciences, University of Sharjah, Sharjah, PR:ADDRESS UAE, Sharjah, 000, United Arab Emirates PR:EMAIL tims-tof@sharjah.ac.ae PR:PHONE +971 6 5057656 #STUDY ST:STUDY_TITLE Mass spectroscopy‑based proteomics and metabolomics analysis of ST:STUDY_TITLE triple‑positive breast cancer cells treated with tamoxifen ST:STUDY_SUMMARY HER2-enriched breast cancer with high levels of hormone receptor expression, ST:STUDY_SUMMARY known as "triple positive" breast cancer, may represent a new entity with a ST:STUDY_SUMMARY relatively favourable prognosis against which the combination of chemotherapy, ST:STUDY_SUMMARY HER-2 inhibition, and endocrine treatment may be considered overtreatment. We ST:STUDY_SUMMARY explored the effect of the anticancer drugs tamoxifen and trastuzumab, both ST:STUDY_SUMMARY separately and in combination, on the integrated proteomic and metabolic profile ST:STUDY_SUMMARY of "triple positive" breast cancer cells (BT-474). Method We employed ST:STUDY_SUMMARY ultra-high-performance liquid chromatography-quadrupole time of flight mass ST:STUDY_SUMMARY spectrometry using a Bruker timsTOF to investigate changes in BT-474 cell line ST:STUDY_SUMMARY treated with either tamoxifen, trastuzumab or a combination. Differentially ST:STUDY_SUMMARY abundant metabolites were identified using the Bruker Human Metabolome Database ST:STUDY_SUMMARY metabolite library and proteins using the Uniprot proteome for Homo sapiens ST:STUDY_SUMMARY using MetaboScape and MaxQuant, respectively, for identification and ST:STUDY_SUMMARY quantitation. Results A total of 77 proteins and 85 metabolites were found to ST:STUDY_SUMMARY significantly differ in abundance in BT-474 treated cells with tamoxifen 5 ST:STUDY_SUMMARY μM/and or trastuzumab 2.5 μM. Findings suggest that by targeting important ST:STUDY_SUMMARY cellular signalling pathways which regulate cell growth, apoptosis, ST:STUDY_SUMMARY proliferation, and chemoresistance, these medicines have a considerable ST:STUDY_SUMMARY anti-growth effect in BT-474 cells. Pathways enriched for dysregulation include ST:STUDY_SUMMARY RNA splicing, neutrophil degranulation and activation, cellular redox ST:STUDY_SUMMARY homeostasis, mitochondrial transmembrane transport, ferroptosis and necroptosis, ST:STUDY_SUMMARY ABC transporters and central carbon metabolism. Conclusion Our findings in ST:STUDY_SUMMARY protein and metabolite level research revealed that anti-cancer drug therapy had ST:STUDY_SUMMARY a significant impact on the key signalling pathways and molecular processes in ST:STUDY_SUMMARY triple positive BT-474 cell lines. ST:INSTITUTE University of Sharjah ST:DEPARTMENT Sharjah Institute for Medical Research ST:LABORATORY Biomarker Discovery Group ST:LAST_NAME Soares ST:FIRST_NAME Nelson ST:ADDRESS M32, SIMR, College of Pharmacy, Health Sciences, University of Sharjah ST:EMAIL nsoares@sharjah.ac.ae ST:PHONE 065057656 #SUBJECT SU:SUBJECT_TYPE Human SU:SUBJECT_SPECIES Homo sapiens SU:TAXONOMY_ID 9606 #FACTORS #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data SUBJECT_SAMPLE_FACTORS - 1A_93_1_328 Treatment:Control RAW_FILE_NAME=1A''_93_1_328.d SUBJECT_SAMPLE_FACTORS - 1A_93_1_331 Treatment:Control RAW_FILE_NAME=1A''_93_1_331.d SUBJECT_SAMPLE_FACTORS - 1A_92_1_327 Treatment:Control RAW_FILE_NAME=1A'_92_1_327.d SUBJECT_SAMPLE_FACTORS - 1A_92_1_330 Treatment:Control RAW_FILE_NAME=1A'_92_1_330.d SUBJECT_SAMPLE_FACTORS - 1A_91_1_326 Treatment:Control RAW_FILE_NAME=1A_91_1_326.d SUBJECT_SAMPLE_FACTORS - 1A_91_1_329 Treatment:Control RAW_FILE_NAME=1A_91_1_329.d SUBJECT_SAMPLE_FACTORS - 2a_-1_59_1_440 Treatment:TAMOXIFEN RAW_FILE_NAME=2a''_-1_59_1_440.d SUBJECT_SAMPLE_FACTORS - 2a_-2_59_1_441 Treatment:TAMOXIFEN RAW_FILE_NAME=2a''_-2_59_1_441.d SUBJECT_SAMPLE_FACTORS - 2a_-1_58_1_438 Treatment:TAMOXIFEN RAW_FILE_NAME=2a'_-1_58_1_438.d SUBJECT_SAMPLE_FACTORS - 2a_-2_58_1_439 Treatment:TAMOXIFEN RAW_FILE_NAME=2a'_-2_58_1_439.d SUBJECT_SAMPLE_FACTORS - 2a-1_57_1_436 Treatment:TAMOXIFEN RAW_FILE_NAME=2a-1_57_1_436.d SUBJECT_SAMPLE_FACTORS - 2a-2_57_1_437 Treatment:TAMOXIFEN RAW_FILE_NAME=2a-2_57_1_437.d #COLLECTION CO:COLLECTION_SUMMARY The BT-474 BC cell line utilized in this study was cultured as monolayers in CO:COLLECTION_SUMMARY DMEM medium supplemented with 10% fetal bovine serum and 1% CO:COLLECTION_SUMMARY penicillin/streptomycin (Sigma Aldrich, St. Louis, MO, USA). All cultures were CO:COLLECTION_SUMMARY incubated at 37 °C in a humidified atmosphere of 5% CO2. CO:SAMPLE_TYPE Breast cancer cells CO:STORAGE_CONDITIONS Described in summary #TREATMENT TR:TREATMENT_SUMMARY Triplicate flasks were prepared for each treatment condition for each analysis TR:TREATMENT_SUMMARY (metabolomic and proteomic) for a total of 24 flasks. Two million cells were TR:TREATMENT_SUMMARY seeded in each 75 cm2 tissue culture flask and incubated for 24 h. The cells TR:TREATMENT_SUMMARY were then treated with Tamoxifen (5 μM) and/or Trastuzumab (2.5 μM) for 24 h. TR:TREATMENT_SUMMARY These concentrations correspond to the IC50 of these compounds with BT-474 TR:TREATMENT_SUMMARY cells, as determined by cytotoxicity assays (data not shown). Control cells were TR:TREATMENT_SUMMARY treated with vehicle (dimethyl sulfoxide (DMSO) at 0.5% for 24 h. Following the TR:TREATMENT_SUMMARY incubation period, cells were collected by trypsinization and washed twice with TR:TREATMENT_SUMMARY phosphate-buffered saline solution (PBS) before re-suspending in 1 mL 1 × PBS TR:TREATMENT_SUMMARY for further analysis. Finally, cells were collected as pellets by centrifugation TR:TREATMENT_SUMMARY at 1200 rounds per minute (rpm) for 10 min at room temperature. To negate the TR:TREATMENT_SUMMARY effect of Circadian rhythms on the response of cells to treatment, cells were TR:TREATMENT_SUMMARY kept under the same conditions during the entire incubation period and the cell TR:TREATMENT_SUMMARY collection was done concurrently for all samples. In addition, the same number TR:TREATMENT_SUMMARY of cells were used for each sample to avoid the effect of variation in cell TR:TREATMENT_SUMMARY numbers. TR:TREATMENT Drugs TR:TREATMENT_COMPOUND Tamoxifen and/or Trastuzumab #SAMPLEPREP SP:SAMPLEPREP_SUMMARY Sample metabolite extraction A volume of 1 mL of the extraction solvent SP:SAMPLEPREP_SUMMARY (methanol+0.1% formic acid) was added to the cell pellets to quench cells. The SP:SAMPLEPREP_SUMMARY cells were then vortexed for 2 min to ensure the quantitative extraction of the SP:SAMPLEPREP_SUMMARY metabolites and stored on ice for 1 h, during which the samples were vortexed SP:SAMPLEPREP_SUMMARY every 15 min. After this, the insoluble cell matrices were collected and SP:SAMPLEPREP_SUMMARY transferred to centrifuge tubes, intermittent ultrasonication using the COPLEY SP:SAMPLEPREP_SUMMARY sonicator (QSONICA SONICATOR, USA) under 30% amplifier and for 30 s with an ice SP:SAMPLEPREP_SUMMARY bath employed throughout the process. Following that, cells debris were then SP:SAMPLEPREP_SUMMARY centrifuged (15,000 rpm, 10 min, − 4 °C) and the sample supernatants were SP:SAMPLEPREP_SUMMARY collected and transferred to LC vials for drying in the EZ-2 Plus SP:SAMPLEPREP_SUMMARY (GeneVac-Ipswich, UK) at 37±1 °C. Dried samples were resuspended with 200 µL SP:SAMPLEPREP_SUMMARY (water+0.1% formic acid), and vortexed for 2 min. Finally, the samples were SP:SAMPLEPREP_SUMMARY filtered using a hydrophilic Nylon Syringe Filter of 0.45 µm pore size and SP:SAMPLEPREP_SUMMARY analyzed by Q-TOF MS SP:PROCESSING_STORAGE_CONDITIONS Described in summary SP:EXTRACT_STORAGE Described in summary #CHROMATOGRAPHY CH:CHROMATOGRAPHY_SUMMARY Samples were chromatographically separated by inline reversed-phase CH:CHROMATOGRAPHY_SUMMARY chromatography using the Elute HPG 1300 pumps and Elute Autosampler (Bruker, CH:CHROMATOGRAPHY_SUMMARY Darmstadt, Germany) with solvent A 0.1% FA in HPLC grade water and solvent B CH:CHROMATOGRAPHY_SUMMARY 0.1% FA in ACN. A Hamilton Intensity Solo 2 C18 column (100 mm × 2.1 mm, 1.8 CH:CHROMATOGRAPHY_SUMMARY μm beads) was maintained at 35 ℃ (metabolomics analyses). CH:CHROMATOGRAPHY_TYPE Reversed phase LC CH:INSTRUMENT_NAME Bruker Elute HPG 1300 CH:COLUMN_NAME Hamilton Intensity Solo 2 C18 CH:FLOW_GRADIENT 1%B to 99%B in 15 min CH:FLOW_RATE 250 uL/min CH:COLUMN_TEMPERATURE 35 CH:METHODS_FILENAME . CH:SOLVENT_A Water (0.1% Formic Acid) CH:SOLVENT_B ACN (0.1% Formic Acid) CH:METHODS_ID . CH:COLUMN_PRESSURE . CH:INJECTION_TEMPERATURE . CH:INTERNAL_STANDARD . CH:INTERNAL_STANDARD_MT . CH:RETENTION_INDEX . CH:RETENTION_TIME . CH:SAMPLE_INJECTION . CH:SAMPLING_CONE . CH:ANALYTICAL_TIME . CH:CAPILLARY_VOLTAGE . CH:MIGRATION_TIME . CH:OVEN_TEMPERATURE 35C CH:PRECONDITIONING . CH:RUNNING_BUFFER . CH:RUNNING_VOLTAGE . CH:SHEATH_LIQUID . CH:TIME_PROGRAM . CH:TRANSFERLINE_TEMPERATURE . CH:WASHING_BUFFER . CH:WEAK_WASH_SOLVENT_NAME . CH:WEAK_WASH_VOLUME . CH:STRONG_WASH_SOLVENT_NAME . CH:STRONG_WASH_VOLUME . CH:TARGET_SAMPLE_TEMPERATURE . CH:SAMPLE_LOOP_SIZE . CH:SAMPLE_SYRINGE_SIZE . CH:RANDOMIZATION_ORDER . CH:CHROMATOGRAPHY_COMMENTS . #ANALYSIS AN:ANALYSIS_TYPE MS #MS MS:INSTRUMENT_NAME Bruker timsTOF MS:INSTRUMENT_TYPE QTOF MS:MS_TYPE ESI MS:ION_MODE POSITIVE MS:MS_COMMENTS The MS analysis was performed using a timsTOF (Bruker, Darmstadt, Germany) with MS:MS_COMMENTS Apollo II electrosprayionization (ESI) source. The drying gas was set to flow at MS:MS_COMMENTS 10 L/min and the drying temperature to 220℃ and the nebulizer pressure to 2.2 MS:MS_COMMENTS bar. The capillary voltage was 4500 V and the end plate offset 500 V. For MS:MS_COMMENTS metabolomics 20–1300 m/z. The instrument was operated in auto-MS/MS mode. For MS:MS_COMMENTS metabolomics the collision energy was set to 20 eV, the cycle time to 0.5 s with MS:MS_COMMENTS a relative minimum intensity threshold of 400 counts per thousand and a target MS:MS_COMMENTS intensity of 20,000. Sodium formate was injected as an external calibrant in the MS:MS_COMMENTS first 0.3 min of each LC–MS/MS run. #MS_METABOLITE_DATA MS_METABOLITE_DATA:UNITS AU MS_METABOLITE_DATA_START Samples 1A_93_1_328 1A_93_1_331 1A_92_1_327 1A_92_1_330 1A_91_1_326 1A_91_1_329 2a_-1_59_1_440 2a_-2_59_1_441 2a_-1_58_1_438 2a_-2_58_1_439 2a-1_57_1_436 2a-2_57_1_437 Factors Treatment:Control Treatment:Control Treatment:Control Treatment:Control Treatment:Control Treatment:Control Treatment:TAMOXIFEN Treatment:TAMOXIFEN Treatment:TAMOXIFEN Treatment:TAMOXIFEN Treatment:TAMOXIFEN Treatment:TAMOXIFEN L-Arginine 1678 2032 1866 1960 2126 2186 2364 2094 2440 1524 1810 2042 L-Proline 254 464 480 314 254 96 1072 1566 700 694 1108 798 L-Acetylcarnitine 0 0 0 0 0 0 16922 15334 14726 15112 21838 21154 Adenosine monophosphate 96 112 90 0 540 108 37020 34826 33290 39654 45808 44182 Cytidine 0 0 0 0 0 0 4216 2906 2462 3958 4378 4090 Pyridine 0 0 0 0 0 0 1066 1130 736 868 1324 590 L-Valine 880 1616 1600 1414 1554 1900 0 0 0 0 216 0 Adenosine 3_,5_-diphosphate 17774 39590 31048 42806 8724 46536 210 318 166 374 386 262 Guanosine monophosphate 4552 7114 7072 7174 20838 6828 120 138 112 188 222 100 Deoxyadenosine monophosphate 1242 1606 1114 1896 0 1944 0 0 0 0 0 0 Pyrrolidonecarboxylic acid 18106 18506 17446 19446 8362 20722 0 0 0 84 0 0 L-Tyrosine 12872 11892 12656 13046 0 13076 236 88 0 226 230 736 Doxylamine 0 0 144 0 254 0 1358 696 1144 0 666 1056 Metoprolol 308 220 272 0 724 756 5626 6786 6228 5900 5314 6724 Phenylacetylglycine 0 0 0 0 0 0 1088 1216 614 1074 882 972 Phosphoric acid 1586 1102 1888 1440 3812 1768 198 96 190 84 0 148 Phenylacetaldehyde 2254 2582 2434 2752 1974 2418 166 0 0 0 0 0 Aspartyl-lysine 3888 5036 4410 4516 3372 4272 0 0 0 118 102 0 3-Methylindole 574 618 1984 1656 1912 1620 0 126 0 0 388 226 Spermine 43390 42606 37734 42484 47050 36178 5648 7588 1676 5248 11416 12500 Glycerophosphocholine 5096 5574 6720 8274 4964 7782 3660 3172 2910 2964 3806 3290 L-Glutamic acid 556 1196 1142 1388 574 1368 400 296 370 338 448 144 Creatine 2148 2514 3084 2904 2892 3080 1980 2500 2046 0 2382 2062 Cytidine monophosphate 2464 2586 2556 2718 2094 3350 908 1332 1646 1820 1162 1688 Uridine diphosphate-N-acetylglucosamine 106 0 0 0 0 0 1354 1550 5148 2210 2822 2948 1-Methyladenosine 114 92 0 166 118 0 2710 2160 1302 2988 3434 2574 Trimethylamine 334 130 0 0 0 118 1552 1028 1074 1648 1960 1420 Omeprazole 0 0 0 0 0 0 1516 998 946 1292 1472 1758 Pyroglutamic acid 204 98 346 330 0 246 15044 10904 7672 10296 11064 11146 Uridine 5_-monophosphate 3466 4380 4728 4634 4004 5194 0 96 0 88 0 92 Glutathione 472754 387742 463994 435460 469518 487416 650 1944 248 426 2716 2766 L-Leucine 2060 1970 1452 1704 2652 1440 360 188 0 200 98 700 Hypoxanthine 0 0 0 0 120 0 46316 37342 206 42056 57578 55478 Inosine 0 0 0 0 0 0 10214 10754 0 12528 19082 18274 Guanosine 0 0 0 0 0 0 19106 14832 0 14496 22470 21688 Guanine 64 140 536 152 648 238 33852 27898 184 30206 36924 29376 Adenosine 67130 60510 70696 59562 252 111320 478 444 190 492 0 0 L-Phenylalanine 0 0 0 0 0 0 27126 24854 15106 19084 28346 27108 Beta-Alanine 0 0 0 0 0 0 4032 2184 1018 1802 2204 2512 5_-Methylthioadenosine 0 0 0 0 0 114 3976 4758 2364 3622 4302 4136 L-Tryptophan 98 172 160 0 174 106 31150 30366 15438 22716 29358 32010 2-Ethyl-2-hydroxybutyric acid 1274 1288 1106 1086 1482 908 188 290 480 206 558 292 Isovalerylcarnitine 0 0 112 0 0 0 7120 6496 3630 5714 4116 4598 Sphingosine 17858 14684 16256 13172 11402 15478 100 0 150 242 0 98 PC_16:0_16:0_ 0 0 0 0 0 0 1962 2382 2890 3370 2526 1610 PC_18:1_9Z_18:1_9Z_ 0 0 0 0 0 0 9510 8784 12142 5972 28374 10916 MS_METABOLITE_DATA_END #METABOLITES METABOLITES_START metabolite_name Bucket label RT m/z Formula L-Arginine 174.11170 Da 68.25 s 1.14 175.11898 C6H14N4O2 L-Proline 115.06312 Da 94.80 s 1.58 116.07039 C5H9NO2 L-Acetylcarnitine 203.11597 Da 96.03 s 1.6 204.12325 C9H17NO4 Adenosine monophosphate 347.06408 Da 96.87 s 1.61 348.07136 C10H14N5O7P Cytidine 243.08577 Da 97.25 s 1.62 244.09304 C9H13N3O5 Pyridine 79.04255 Da 107.09 s 1.78 80.04983 C5H5N L-Valine 117.07895 Da 118.12 s 1.97 118.08623 C5H11NO2 Adenosine 3_,5_-diphosphate 427.03111 Da 145.94 s 2.43 428.03838 C10H15N5O10P2 Guanosine monophosphate 363.05925 Da 149.86 s 2.5 364.06653 C10H14N5O8P Deoxyadenosine monophosphate 331.06886 Da 152.48 s 2.54 332.07614 C10H14N5O6P Pyrrolidonecarboxylic acid 129.04249 Da 163.68 s 2.73 130.04976 C5H7NO3 L-Tyrosine 181.07404 Da 233.80 s 3.9 182.08132 C9H11NO3 Doxylamine 270.17124 Da 372.87 s 6.21 271.17852 C17H22N2O Metoprolol 267.18348 Da 450.22 s 7.5 268.19076 C15H25NO3 Phenylacetylglycine 193.07427 Da 455.64 s 7.59 194.08155 C10H11NO3 Phosphoric acid 97.97680 Da 583.94 s 9.73 98.98407 H3O4P Phenylacetaldehyde 120.05739 Da 776.22 s 12.94 121.06466 C8H8O Aspartyl-lysine 261.13684 Da 789.33 s 13.16 262.14411 C10H19N3O5 3-Methylindole 131.07341 Da 889.82 s 14.83 132.08069 C9H9N Spermine 202.21584 Da 57.30 s 0.95 203.22312 C10H26N4 Glycerophosphocholine 257.10296 Da 74.01 s 1.23 258.11023 C8H20NO6P L-Glutamic acid 147.05315 Da 78.68 s 1.31 148.06043 C5H9NO4 Creatine 131.06934 Da 81.54 s 1.36 132.07661 C4H9N3O2 Cytidine monophosphate 323.05212 Da 85.38 s 1.42 324.0594 C9H14N3O8P Uridine diphosphate-N-acetylglucosamine 607.08422 Da 95.47 s 1.59 608.0915 C17H27N3O17P2 1-Methyladenosine 281.11293 Da 96.96 s 1.62 282.12021 C11H15N5O4 Trimethylamine 59.07376 Da 96.06 s 1.6 60.08103 C3H9N Omeprazole 345.11832 Da 98.27 s 1.64 346.12559 C17H19N3O3S Pyroglutamic acid 129.04263 Da 103.43 s 1.72 130.04985 C5H7NO3 Uridine 5_-monophosphate 324.03634 Da 134.02 s 2.23 325.04361 C9H13N2O9P Glutathione 307.08436 Da 148.37 s 2.47 308.09163 C10H17N3O6S L-Leucine 131.09482 Da 213.47 s 3.56 132.1021 C6H13NO2 Hypoxanthine 136.03838 Da 285.18 s 4.75 137.04565 C5H4N4O Inosine 268.08034 Da 285.40 s 4.76 269.08761 C10H12N4O5 Guanosine 283.09106 Da 285.52 s 4.76 284.09834 C10H13N5O5 Guanine 151.04925 Da 285.51 s 4.76 152.05652 C5H5N5O Adenosine 267.09682 Da 304.38 s 5.07 268.1041 C10H13N5O4 L-Phenylalanine 165.07899 Da 313.32 s 5.22 166.08626 C9H11NO2 Beta-Alanine 89.04761 Da 335.29 s 5.59 90.05488 C3H7NO2 5_-Methylthioadenosine 297.09013 Da 356.85 s 5.95 298.09741 C11H15N5O3S L-Tryptophan 204.09035 Da 366.10 s 6.1 205.09763 C11H12N2O2 2-Ethyl-2-hydroxybutyric acid 132.07829 Da 379.55 s 6.33 133.08557 C6H12O3 Isovalerylcarnitine 245.16271 Da 389.28 s 6.49 246.16999 C12H23NO4 Sphingosine 299.28329 Da 752.77 s 12.55 282.27997 C18H37NO2 PC_16:0_16:0_ 733.56294 Da 871.19 s 14.52 734.57022 C40H80NO8P PC_18:1_9Z_18:1_9Z_ 785.59742 Da 1155.44 s 19.26 786.6047 C44H84NO8P METABOLITES_END #END